Blog
    Peptide SpotlightFor PhysiciansApril 3, 2026

    CJC-1295: GH Secretion and Phase II Safety Concerns

    Review the clinical evidence on CJC-1295, its effects on GH and IGF-1 levels, and the safety concerns that led to the discontinuation of Phase II trials.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Clinical Question

    How does the synthetic growth hormone-releasing hormone (GHRH) analog CJC-1295 influence the secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), and what are the clinical safety implications of its extended half-life?

    Evidence Snapshot

    • Evidence Grade: B-
    • Peptide Type: Synthetic 30-amino acid GHRH analog.
    • Study Type: Phase II Clinical Trials (Discontinued).
    • Primary Outcomes: Sustained 2-10x increase in GH for 6+ days; dose-dependent IGF-1 increases.
    • Regulatory Status: Not approved; Phase II development halted; FDA Category 2 status withdrawn September 2024.

    What the Research Shows

    Research into CJC-1295 identifies it as a synthetic analog of GHRH capable of exerting prolonged physiological effects. Data indicates that administration results in a significant, dose-dependent increase in both GH and IGF-1 secretion. Specifically, clinical observation noted a 2-fold to 10-fold increase in GH levels that persisted for more than six days following administration.

    A critical inflection point in the research occurred during Phase II development. The clinical trial program, managed by ConjuChem, was discontinued following the death of a participant. Consequently, no further formal development has been pursued, and the available evidence remains incomplete.

    Notably, the research lacks any randomized controlled trial (RCT) data regarding body composition or physical performance outcomes. Furthermore, clinical literature highlights frequent confusion between CJC-1295 (which includes the Drug Affinity Complex) and modified GRF 1-29 (often called CJC-1295 without DAC).

    Mechanism

    CJC-1295 functions as a GHRH analog that incorporates a Drug Affinity Complex (DAC). This complex allows the peptide to covalently bind to endogenous albumin. This binding mechanism extends the peptide's half-life to approximately 6-8 days and provides resistance to degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).

    Upon administration, the peptide stimulates the secretion of GH and IGF-1. A distinctive feature of this mechanism is its reported ability to preserve the natural pulsatile pattern of growth hormone secretion while maintaining elevated baseline levels. This sustained secretion is dose-dependent.

    Limitations of the Evidence

    The evidence base for CJC-1295 is significantly constrained by the discontinuation of its Phase II clinical trial. Because the trial was halted due to a participant death, the safety profile is poorly defined and incomplete. Regulatory bodies have noted specific safety concerns, including an increase in heart rate.

    There is a total absence of peer-reviewed human data regarding secondary endpoints such as athletic performance, fat mass reduction, or muscle tissue accretion, as no RCTs reached completion to report on these outcomes. Additionally, the widespread conflation of CJC-1295 with GHRH analogs lacking the DAC component complicates the interpretation of existing data.

    From a regulatory perspective, CJC-1295 is not FDA-approved. It was moved to Category 2 in September 2023, but the nomination was subsequently withdrawn, and it was removed from the list in September 2024. A warning letter was issued in 2020 to Tailor Made referencing the peptide.

    Clinical Takeaway

    CJC-1295 demonstrates a potent ability to elevate GH and IGF-1 concentrations for extended periods due to its albumin-binding DAC modification. However, the interruption of Phase II trials following a participant death and the lack of data on functional outcomes create significant gaps in its clinical risk-benefit profile. Regulatory agencies currently categorize it as a substance with safety concerns, including cardiovascular effects.

    Sources

    • TruthTides Compound Database: CJC-1295 (Grade B-).
    • Clinical Trial Record: Phase II Various (ConjuChem), ID: 7d0b97b8-52eb-4026-a3ee-9f7170ade29d.
    • Regulatory Status: FDA 503A/503B Records; Warning Letter (Tailor Made, 2020).

    Referenced Peptides

    ipamorelingrowth hormone releasing hormone

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.